Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance Journal Article


Authors: Palazzo, M.; Shah, G. L.; Copelan, O.; Seier, K.; Devlin, S. M.; Maloy, M.; Kenny, S.; Hassoun, H.; Korde, N. S.; Lendvai, N.; Lesokhin, A. M.; Mailankody, S.; Chung, D. J.; Koehne, G.; Landgren, C. O.; Landau, H.; Giralt, S. A.; Perales, M. A.
Article Title: Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance
Abstract: Guidelines recommend vaccination starting 12 months after autologous hematopoietic stem cell transplant (aHCT), but there is varying practice for patients on maintenance therapy, with some centers not immunizing at all. Because of decreased vaccine rates among the general population causing loss of herd immunity, we aimed to establish the safety and efficacy of revaccinating multiple myeloma patients on lenalidomide maintenance (LM). Of the 122 patients who were vaccinated after aHCT between 2010 and 2014 at Memorial Sloan Kettering Cancer Center, 91 (75%) were on LM. Vaccine responses were defined by increases between pre- and postvaccination titers. Reponses varied by vaccine type with 76% responding to pertussis, 70% diphtheria, 60% tetanus, 71% Haemophilus influenzae, and 58% pneumococcal. All patients retained minimal levels of polio immunity, but 27% responded with increased titers. Fewer patients received hepatitis A and B, but of those who did, 30% responded to hepatitis A and 40% to hepatitis B. No differences were seen in rates of response for those on LM at time of vaccination compared with those who were not. There were no vaccine-related adverse effects. Reimmunization with inactivated vaccines in patients on LM is therefore both safe and effective, offering this population immunity to vaccine-preventable diseases. © 2017 The American Society for Blood and Marrow Transplantation
Keywords: lenalidomide; multiple myeloma; vaccination; immunization; maintenance; autologous transplant
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 24
Issue: 4
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2018-04-01
Start Page: 871
End Page: 876
Language: English
DOI: 10.1016/j.bbmt.2017.12.795
PROVIDER: scopus
PUBMED: 29288818
DOI/URL:
Notes: Article -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Sergio Andres Giralt
    535 Giralt
  2. Hani Hassoun
    149 Hassoun
  3. Miguel-Angel Perales
    378 Perales
  4. Guenther Koehne
    175 Koehne
  5. Heather Jolie Landau
    187 Landau
  6. Nikoletta Lendvai
    85 Lendvai
  7. Sheila A Kenny
    5 Kenny
  8. Alexander Meyer Lesokhin
    117 Lesokhin
  9. David Chung
    83 Chung
  10. Molly Anna Maloy
    131 Maloy
  11. Sean McCarthy Devlin
    303 Devlin
  12. Carl Ola Landgren
    195 Landgren
  13. Neha Sanat Korde
    64 Korde
  14. Gunjan Lalitchandra Shah
    81 Shah
  15. Kenneth Seier
    22 Seier